A Phase 4 interventional study of Varenicline Pill and Hydroxyzine Pill in Smoking Cessation, Stress and Sleep Disturbance, sponsored by Rose Research Center, LLC. Completed at 2 sites in United States. Open to participants aged 19 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-03.
Sponsored by Rose Research Center, LLC · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies testing varenicline in Smoking Cessation — 5 open to participants now, 7 under way, 2 of them phase 3. Varenicline · Smoking Cessation.
Among the 110 studies testing varenicline in Smoking Cessation, this one is the 95th largest by enrollment, is one of 6 that started in 2019, is one of 47 in phase 4, and was the 93rd registered.
1,582 studies on the registry are indexed under Smoking Cessation; 198 are open to participants now.
Browse Smoking Cessation studies →5 of the 110 studies testing varenicline in Smoking Cessation are open now, in 4 countries. Recruiting first, the newest first:
University of Wisconsin, Madison · Sites in United States
Ages 21+
University of Colorado, Denver · Sites in United States, India
Ages 18+
Johns Hopkins University · Sites in South Africa
Ages 18+
University of Maryland, Baltimore · Sites in Botswana
Ages 18+ · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 18+
By country, each count listing its studies:
Varenicline: first FDA approval 2006 (CHANTIX), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 137 Smoking Cessation studies recruiting now, 93 (68%) set no upper age limit and 37 (27%) stop at 75 or younger; 6 take children under 18; 41 take healthy volunteers.
This study: 19 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 25 · Phase 3 30 · Phase 4 47
First in 2000; this study’s year is marked. 6 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 26 is below the median of 164 across 1,424 interventional studies indexed under Smoking Cessation.
Median enrollment 209 across the 110 interventional studies. Of the 97 that completed or were terminated, 61 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 110 have an industry lead sponsor. The 10 most frequent:
Rose Research Center, LLC is the lead sponsor of 13 studies on the registry; none are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 3 (38%) have results posted.
10 studies in Smoking Cessation by Rose Research Center, LLC: none open now, none under way, none of them phase 3. Of 9 finished, 4 (44%) have results posted.
Among the 10 studies in Smoking Cessation by Rose Research Center, LLC, this one is the 4th largest by enrollment, is one of 3 that started in 2019, is the only one in phase 4, and was the 1st registered.
Rose Research Center, LLC’s Smoking Cessation studies by the year they started, since 2019.
2 of the studies testing varenicline in Smoking Cessation that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05413122Phase 3Johns Hopkins UniversityEvaluating Smoking Cessation Interventions for PWH in South Africa | 2027-08-31 |
| NCT05694637University of Maryland, BaltimoreBotswana Smoking and Abstinence Reinforcement Trial | 2027-02-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 110 studies testing varenicline in Smoking Cessation, from their registry updates:
Among Rose Research Center, LLC’s 10 in Smoking Cessation:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This open-label study will evaluate hydroxyzine, a first-generation antihistamine, combined with varenicline, to help smokers abstain from smoking during a 12-week trial period by diminishing the nausea, stress, anxiety, and sleep disturbances associated with the use of varenicline and with nicotine withdrawal.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants enrolled in the study will take the FDA approved starter kit of varenicline for the first week of medication administration (0.5 mg nightly for days 1-3, then 0.5 mg twice daily for days 4-7). During the first week, participants will also receive hydroxyzine dosed in a similar manner, 50 mg nightly for the first 3 days, then twice daily, 25 mg in the morning and 50 mg at night. After the first week, participants will receive the FDA-approved dose of varenicline (1 mg twice daily) combined with hydroxyzine, 25 mg in the morning and 50 mg at nighttime. All medications will be dosed orally.
Drug: Varenicline Pill · Drug: Hydroxyzine Pill
FDA approved starter kit of varenicline (0.5 mg nightly for days 1-3, then 0.5 mg twice daily for days 4-7) followed by FDA-approved dose of varenicline (1 mg twice daily) for the remaining 11 weeks
Also known as: Chantix
For the first week, participants will receive 50 mg nightly for the first 3 days, then twice daily, 25 mg in the morning and 50 mg at night for the remaining 12 weeks.
Change in 10-item Perceived Stress Scale (PSS-10) Following Smoking Cessation (While Taking Arenicline and Hydroxyzine).
Stress levels in the last 30 days will be measured using the 10-item Perceived Stress Scale (PSS-10). The PSS-10 uses a 5-point scale (0 - never, 1 = almost never, 2 = once in a while, 3 = often, 4 = very often). Total scores range from 0 to 40. * Scores ranging from 0-13 would be considered low stress. * Scores ranging from 14-26 would be considered moderate stress. * Scores ranging from 27-40 would be considered high perceived stress.
Time frame: Weeks 1, 2, 4, 8, 12
Changes in Anxiety Using the 6-item State-Trait Anxiety Inventory (STAI)
Trait and state anxiety levels will be monitored for changes using the 6-item State-Trait Anxiety Inventory (STAI). All items are rated on a 4-point scale ("1-Almost Never" to "4-Almost Always"). The range of scores is from 6 to 24. Higher scores indicate greater anxiety.
Time frame: Weeks 1, 2, 4, 8, 12
Changes in Depression Using the Patient Health Questionnaire (PHQ-9)
Depression will be monitored for changes using the Patient Health Questionnaire (PHQ-9). The PHQ-9 uses a 4-point scale (Not at all = 0; Several days = 1;More than half the days = 2; Nearly every day = 3). The sum of the scores is calculated (Score range is 0 to 27): * 1-4 Minimal depression * 5-9 Mild depression * 10-14 Moderate depression * 15-19 Moderately severe depression * 20-27 Severe depression
Time frame: Weeks 1, 2, 4, 8, 12
Effects of Varenicline on Self-reported Smoking Reduction Prior to the Quit Date
Previous research has shown that abstinence at the end of treatment is strongly predicted by the extent to which smokers spontaneously reduce ad libitum smoking in the initial weeks of pharmacotherapy that is initiated before the quit-smoking date. This measure will assess the extent of smoking reduction in participants during the initial seven days of treatment (prior to their planned quit date) - assessed via a self-report number of cigarettes per day. Data is recorded as a mean change.
Time frame: 7 Days
Effects of Varenicline on Self-reported Smoking Reduction Prior to the Quit Date
Previous research has shown that abstinence at the end of treatment is strongly predicted by the extent to which smokers spontaneously reduce ad libitum smoking in the initial weeks of pharmacotherapy that is initiated before the quit-smoking date. This measure will assess the extent of smoking reduction in participants during the initial seven days of treatment (prior to their planned quit date) - assessed via expired air carbon monoxide (CO). Data is recorded as a mean change.
Time frame: 7 Days
The study was conducted in both the Raleigh, NC and Charlotte, NC offices of Rose Research Center. Enrollment started on 17 June 2019 and ended on 16 September 2019.
| Milestone | Hydroxyzine and Varenicline |
|---|---|
| Started | 26 |
| Completed | 20 |
| Not completed | 6 |
| Withdrew: Lost to follow-up | 5 |
| Withdrew: Non-compliance | 1 |
Stress levels in the last 30 days will be measured using the 10-item Perceived Stress Scale (PSS-10). The PSS-10 uses a 5-point scale (0 - never, 1 = almost never, 2 = once in a while, 3 = often, 4 = very often). Total scores range from 0 to 40. * Scores ranging from 0-13 would be considered low stress. * Scores ranging from 14-26 would be considered moderate stress. * Scores ranging from 27-40 would be considered high perceived stress.
| score on a scale | Hydroxyzine and Varenicline |
|---|---|
| Change in PPS-10 from BL to Week 1 | -1.38 ± 2.37 |
| Change in PPS-10 from BL to Week 2 | -1.48 ± 3 |
| Change in PPS-10 from BL to Week 4 | -1.55 ± 2.65 |
| Change in PPS-10 from BL to Week 8 | -2.05 ± 3.58 |
| Change in PPS-10 from BL to Week 12 | -2.75 ± 3.43 |
Trait and state anxiety levels will be monitored for changes using the 6-item State-Trait Anxiety Inventory (STAI). All items are rated on a 4-point scale ("1-Almost Never" to "4-Almost Always"). The range of scores is from 6 to 24. Higher scores indicate greater anxiety.
| score on a scale | Hydroxyzine and Varenicline |
|---|---|
| Change in STAI from BL to Week 1 | -0.54 ± 2.67 |
| Change in STAI from BL to Week 2 | -1.09 ± 3.79 |
| Change in STAI from BL to Week 4 | -0.86 ± 4.54 |
| Change in STAI from BL to Week 8 | -1.82 ± 3.35 |
| Change in STAI from BL to Week 12 | -1.65 ± 3.59 |
Depression will be monitored for changes using the Patient Health Questionnaire (PHQ-9). The PHQ-9 uses a 4-point scale (Not at all = 0; Several days = 1;More than half the days = 2; Nearly every day = 3). The sum of the scores is calculated (Score range is 0 to 27): * 1-4 Minimal depression * 5-9 Mild depression * 10-14 Moderate depression * 15-19 Moderately severe depression * 20-27 Severe depression
| score on a scale | Hydroxyzine and Varenicline |
|---|---|
| Change in PHQ-9 from BL to Week 1 | -0.15 ± 1.12 |
| Change in PHQ-9 from BL to Week 2 | 0.63 ± 2.16 |
| Change in PHQ-9 from BL to Week 4 | 0.43 ± 2.95 |
| Change in PHQ-9 from BL to Week 8 | -0.27 ± 2.07 |
| Change in PHQ-9 from BL to Week 12 | -0.41 ± 1.87 |
Previous research has shown that abstinence at the end of treatment is strongly predicted by the extent to which smokers spontaneously reduce ad libitum smoking in the initial weeks of pharmacotherapy that is initiated before the quit-smoking date. This measure will assess the extent of smoking reduction in participants during the initial seven days of treatment (prior to their planned quit date) - assessed via a self-report number of cigarettes per day. Data is recorded as a mean change.
| Cigs smoked per day | Hydroxyzine and Varenicline -- Successful in Quitting Smoking | Hydroxyzine and Varenicline -- Unsuccessful in Quitting Smoking |
|---|---|---|
| Effects of Varenicline on Self-reported Smoking Reduction Prior to the Quit Date | -9.14 ± 2.29 | -5.53 ± 6.80 |
Previous research has shown that abstinence at the end of treatment is strongly predicted by the extent to which smokers spontaneously reduce ad libitum smoking in the initial weeks of pharmacotherapy that is initiated before the quit-smoking date. This measure will assess the extent of smoking reduction in participants during the initial seven days of treatment (prior to their planned quit date) - assessed via expired air carbon monoxide (CO). Data is recorded as a mean change.
| CO in ppm | Hydroxyzine and Varenicline -- Successful in Quitting Smoking | Hydroxyzine and Varenicline -- Unsuccessful in Quitting Smoking |
|---|---|---|
| Effects of Varenicline on Self-reported Smoking Reduction Prior to the Quit Date | -11.00 ± 8.28 | -2.12 ± 10.02 |
Collected over Data were collected during the 12 week treatment period.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Hydroxyzine and Varenicline | 0/26 (0%) | 0/26 (0%) | 21/26 (80.8%) |
| Event | Hydroxyzine and Varenicline |
|---|---|
| NauseaGastrointestinal disorders | 10/26 |
| HypersomnolenceNervous system disorders | 9/26 |
| InsomniaNervous system disorders | 9/26 |
| Mood ChangesPsychiatric disorders | 7/26 |
| HeadacheNervous system disorders | 5/26 |
| Elevated blood pressureCardiac disorders | 4/26 |
| Vivid dreamsNervous system disorders | 4/26 |
| Age, Categorical(Participants) | Hydroxyzine and Varenicline |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 26 |
| >=65 years | 0 |
| Age, Continuous(years) | Hydroxyzine and Varenicline |
|---|---|
| Mean | 42.115 ± 11.25 |
| Sex: Female, Male(Participants) | Hydroxyzine and Varenicline |
|---|---|
| Female | 11 |
| Male | 15 |
| Ethnicity (NIH/OMB)(Participants) | Hydroxyzine and Varenicline |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 26 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Hydroxyzine and Varenicline |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 7 |
| White | 18 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Hydroxyzine and Varenicline |
|---|---|
| United States | 26 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2019 to primary completion in Dec 2019, 5 months.
Results were first posted in Mar 2023, 3 years 2 months after primary completion.
Of 56 phase 4 interventional studies under Smoking Cessation, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 55. This study's 5 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Varenicline
Rose Research Center, LLC